Biogen
| Type | Public |
| HQ | Cambridge, US |
| Founded | 1978 |
| Size (employees) | 7,300 (est) |
| Website | biogen.com |
Biogen was founded in 1978 and is headquartered in Cambridge, US
Report incorrect company information
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Biogen
Michel Vounatsos
CEO
Susan Alexander
EVP
Jeffrey Capello
EVP
Michael Ehlers
EVP
Ginger Gregory
EVP
Chirfi Guindo
EVP
Report incorrect company information
Biogen Office Locations
Biogen has an office in Cambridge
Cambridge, (HQ)
225 Binney St
Report incorrect company information
Biogen Financials and Metrics
Biogen Revenue
Biogen's revenue was reported to be $11.45 b in FY, 2016 which is a 6.4% increase from the previous period.
| USD | |
|---|---|
Revenue (Q1, 2017) | 2.8b |
Net income (Q1, 2017) | 747.5m |
EBIT (Q1, 2017) | 1.0b |
Market capitalization (4-Dec-2018) | 65.0b |
Closing stock price (4-Dec-2018) | 322.7 |
Cash (31-Mar-2017) | 924.0m |
Biogen's current market capitalization is $65 b.
- Source: Company Filings
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 6.9b | 9.7b | 10.8b | 11.4b |
Revenue growth, % | 40% | 11% | 6% | |
General and administrative expense | 1.9b | |||
R&D expense | 2.0b |
Quarterly
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.4b | 2.5b | 2.6b | 2.6b | 2.8b | 2.7b | 2.9b | 3.0b | 2.8b |
General and administrative expense | 576.6m | 570.4m | 560.4m | 491.9m | 477.8m | 497.3m | 492.4m | 462.7m | 499.1m |
R&D expense | 447.3m | 417.2m | 460.5m | 490.7m | 519.9m | 437.3m | 473.1m | 529.0m | 423.4m |
Operating expense total | 1.0b | 987.6m | 1.0b | 982.6m | 997.7m | 934.6m | 965.5m | 991.7m | 922.5m |
- Source: Company Filings
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 602.6m | 1.2b | 1.3b | 2.3b |
Accounts Receivable | 824.4m | 1.3b | 1.2b | 1.4b |
Inventories | 659.0m | 804.0m | 893.4m | 1.0b |
Current Assets | 3.2b | 4.7b | 6.7b | 8.7b |
Quarterly
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 863.2m | 1.2b | 1.5b | 1.3b | 4.1b | 1.1b | 1.4b | 2.1b | 924.0m |
Accounts Receivable | 1.0b | 1.1b | 1.4b | 1.3b | 1.3b | 1.4b | 1.3b | 1.5b | 1.5b |
Inventories | 715.9m | 753.1m | 825.3m | 865.7m | 918.9m | 964.6m | 996.4m | 1.0b | 921.6m |
Current Assets | 3.9b | 4.4b | 5.3b | 5.6b | 9.3b | 7.2b | 7.4b | 8.1b | 6.9b |
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 1.9b | 2.9b | 3.6b | 3.7b |
Depreciation and Amortization | 688.2m | 600.4m | 682.7m | |
Inventories | (240.0m) | (190.0m) | (170.0m) | (165.6m) |
Quarterly
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 723.1m | 856.1m | 820.2m | 924.8m | 1.0b | 969.2m | 1.0b | 1.0b | 747.5m |
Inventories | 865.7m | 918.9m | 964.6m | 996.4m | 1.0b | 921.6m | |||
Accounts Payable | 282.7m | 251.2m | 271.3m | 225.9m | 274.0m | 316.4m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 379.8k |
Financial Leverage | 1.8 x |
Biogen Operating Metrics
Biogen's Training Provided, no. of people was reported to be 40 k in FY, 2016.
| FY, 2016 | |
|---|---|
Phase I Trials Products | 4 |
Phase II Trials Products | 10 |
Phase III Trials Products | 2 |
Training Provided, no. of people | 40 k |
Biogen Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| AliveGen | July 25, 2018 | $27.50 m |
| Karyopharm Therapeutics | January 25, 2018 | $10 m |
Report incorrect company information
Biogen Online and Social Media Presence
22.97k Twitter followers
Biogen has 22.97k Twitter Followers. The number of followers has increased 1.2% month over month and increased 7.2% quarter over quarter
Report incorrect company information
Biogen News and Updates
December 06, 2018
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
CAMBRIDGE, Mass. and CARLSBAD, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Biogen Inc (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB0…
November 30, 2018
CD Antigen Cancer Therapy Global Market 2018 Top Key Players – AryoGen Biopharma , Biocad , Biogen Idec, Celltrion , Genentech and Forecast to 2025
Wiseguyreports.Com Added New Market Research Report On -“Global CD Antigen Cancer Therapy Market 2018 Top Key Players, Production , Growth and Future Demand Forecast to 2025 ”. Posted via Industry Today. Follow us on Twitter @IndustryToday
November 26, 2018
Global Spinal Muscular Atrophy Market Forecast Report 2017-2026 Featuring Biogen, Roche, Novartis & Cytokinetics
DUBLIN, Nov. 26, 2018 /PRNewswire/ -- The "Spinal Muscular Atrophy Market Global Forecast by Countries, Drugs, and Companies" report has been added to ResearchAndMarkets.com's offering. The global spinal muscular atrophy market and provides an all-encompassing analysis of the key growth...
November 22, 2018
New Research on Neurodegenerative Drugs Market 2023 Overview and Analysis, Focusing on top key players - Novartis International AG, Pfizer Inc, Merck Serono, Biogen Idec, Teva Pharmaceutical Industries Ltd and others
The report titled Global Neurodegenerative Drugs market studies the dynamics and growth prospects of the global Neurodegenerative Drugs market. The report evaluates the growth exhibited by the market in the historical study period and includes information covering definition, classification, industr…
November 19, 2018
The Global Market for Antisense & RNAi Therapeutics is Projected to Grow at a CAGR of 8.67% During 2019-2023, Led by Alnylam Pharmaceuticals, Bausch Health, Biogen, and Sarepta Therapeutics
DUBLIN, Nov 19, 2018 /PRNewswire/ -- The "Global Antisense and RNAi Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. The Global Antisense and RNAi Therapeutics Market is projected to grow at a CAGR of 8.67% during the period 2019-2023. The report...
October 26, 2018
Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD)
Three- and four-year data continued to show reduction in amyloid plaque and to suggest a slowing of the rate of clinical decline in patients
Report incorrect company information
Biogen Blogs
October 11, 2018
Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis
Evidence supports potential of serum neurofilament light (sNfL) as clinically useful biomarker in MS; Biogen and Siemens Healthineers collaborate to develop sNfL blood test Real-world data add to the large body of evidence establishing the long-term effectiveness of TECFIDERA and TYSABRI, including
October 06, 2018
New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy
NURTURE study participants were alive and did not require permanent ventilation, in contrast to natural history of spinal muscular atrophy (SMA) Study participants achieved motor milestones with 100 percent sitting independently and 88 percent able to walk Additional data feature biomarkers as an
October 04, 2018
Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease Meeting on October 25-26, 2018
Cambridge, Mass. – October 4, 2018 – Biogen (Nasdaq: BIIB) today announced it will host live webcasts of its oral presentation and keynote address, as well as a Q&A session related to its Alzheimer’s disease investigational therapies, at the upcoming Clinical Trials on Alzheimer’s Disease annual
October 03, 2018
Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS)
CAMBRIDGE, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Data to be presented from the BIIB092 program for progressive supranuclear palsy and BIIB054 program for Parkinson’s disease highlight Biogen’s commitment to furthering movement disorders research Biogen’s Phase 2 PASSPORT study of BIIB092 for PSP
October 02, 2018
Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care
New research further supports the long-term efficacy and well-characterized safety of leading MS products N ovel data generation initiatives aim to improve outcomes and support the continued move toward precision medicine in MS CAMBRIDGE, Mass., Oct. 02, 2018 (GLOBE NEWSWIRE) -- At the 34th
September 18, 2018
Biogen to Report Third Quarter 2018 Financial Results October 23, 2018
Cambridge, Mass.— Biogen Inc. (Nasdaq:BIIB) today announced it will report third quarter 2018 financial results Tuesday, October 23, 2018, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management from 8:00-9:00 am ET.
Biogen Company Life and Culture
Report incorrect company information
Biogen Frequently Asked Questions
When was Biogen founded?
Biogen was founded in 1978.
Who are Biogen key executives?
Biogen's key executives are Michel Vounatsos, Susan Alexander and Jeffrey Capello.
How many employees does Biogen have?
Biogen has 7,300 employees.
What is Biogen revenue?
Latest Biogen annual revenue is $11.4 b.
What is Biogen revenue per employee?
Latest Biogen revenue per employee is $1.6 m.
Who are Biogen competitors?
Competitors of Biogen include Regeneron Pharmaceuticals, Gilead Sciences and Amgen.
Where is Biogen headquarters?
Biogen headquarters is located at 225 Binney St, Cambridge.
Where are Biogen offices?
Biogen has an office in Cambridge.
How many offices does Biogen have?
Biogen has 1 office.